Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06946277
PHASE4

Assessing the Time-Course of Dexmedetomidine-Induced Analgesia Via EEG

Sponsor: China International Neuroscience Institution

View on ClinicalTrials.gov

Summary

Objective: To investigate the temporal dynamics of dexmedetomidine's analgesic effects in the brain using EEG. Methods: Eligible patients scheduled for total hip arthroplasty under intrathecal anesthesia received a continuous infusion of DEX at 1.5 μg/(kg·h) for 15 minutes before neuraxial puncture, followed by an additional 15-minute infusion. The study was divided into three phases: Phase 1: Non-dosing phase (Baseline). Phase 2: DEX preemptive analgesia phase (DEX infusion). Phase 3: DEX cessation phase (Post-infusion). Outcomes: Primary safety outcome: EEG spectral analysis at different phases. Secondary outcomes: NRS scores, postoperative nausea and vomiting (PONV), dizziness, agitation, and time to intestinal exhaust within 48 hours. Intraoperative hemodynamics were also monitored.

Official title: Mapping the Temporal Profile of Dexmedetomidine-Induced Analgesia Via EEG Signatures in Brain

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2025-04-25

Completion Date

2025-05-26

Last Updated

2025-04-27

Healthy Volunteers

No

Interventions

DRUG

Preemptive Analgesia Of Dexmedetomidine

Preemptive Analgesia Of Dexmedetomidine 1.5 μg · kg-1·h-1 before operation

Locations (1)

Xuanwu hospital

Beijing, Beijing Municipality, China